Royalty Pharma plc

RPRX

$20.56B

Large Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaNEW YORK

Royalty Pharma is a private equity investor firm founded in 1996. It purchases the rights to royalties on future drug sales. It claims to own partial rights to 7 of the top 30 selling drugs in the United States.

Website

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Aug 5, 2026

26d

Market Overview

Stock performance and key metrics

RPRX News

Catalyst Timeline

1 upcoming, 0 past

No catalysts found.

1 more catalyst beyond 14 days

Start a 48-hour free trial to see all upcoming catalysts

Pro

How RPRX's past catalysts played out

earningsNov 2025+7%earningsMay 2022-6%

Drug Pipeline

No drugs found in this phase.

📑

Catalyst DossierPRO

The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.

→

Catalyst Verdict

Full breakdown — the signals behind the verdict

Market-Implied Move

Regulatory Approvals

Frequently asked questions

When is Royalty Pharma plc's next FDA catalyst?→

Royalty Pharma plc's (RPRX) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track RPRX biotech catalysts?→

Add RPRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Royalty Pharma plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply